CTXR · Citius Pharmaceuticals, Inc.

Substantial doubt about the company's ability to continue as a going concern.

“The accompanying unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We incurred a net loss of $37,503,635 for the six months ended March 31, 2026. The Company experienced negative cash flows from operations of $14,308,843 for the six months ended March 31, 2026. At March 31, 2026, the Company had $4,590,174 in cash and a negative working capital of approximately $23.3 million.”